Pharmacy operations update
MedPal AI plc reported a strong operational performance for its automated pharmacy in January 2026, dispensing 36,951 items, a 10.5% increase from December 2025. This volume supports monthly pharmacy revenue exceeding £350,000, based on an average item value of £9.70. The company attributes this sustained growth to its AI triage system, robotic dispensing infrastructure, and increasing patient demand for both NHS and private prescriptions, including through its MedPal.clinic weight-loss platform.
Select text to share a quote on X · sign in to keep highlights & notes in your MPAL notes
MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health company, is pleased to announce the continued strong performance of automated pharmacy operations at its wholly-owned subsidiary, MedPal Limited. MedPal AI combines its user-friendly mobile app, AI-driven diagnosis and triage with human-in-the-loop clinical oversight and prescribing services, with high-tech robotic pharmacy dispensing.
January 2026 Dispensing Performance
The Company is pleased to report that its pharmacy operations dispensed 36,951 items during January 2026, representing growth of 10.5% compared to 33,433 items dispensed in December 2025. Based on an average item value of £9.70, this volume of activity continues to support monthly pharmacy revenue in excess of £350,000 per month.
This sustained growth in dispensing volumes further demonstrates the effectiveness of the Company's advanced AI triage system and state-of-the-art robotic dispensing infrastructure, together with increasing patient demand for both NHS and private prescription services, including through the MedPal.clinic weight-loss platform.
Jason Drummond, CEO of MedPal AI, commented:
"January has delivered another excellent month of growth, with over 10% more prescriptions dispensed than in December. This performance reflects the scalability and resilience of our automated pharmacy model and reinforces our confidence in the ongoing expansion of our digital health offering."
The Board continues to closely monitor trading and will provide further updates as appropriate.
The Directors of the Company are responsible for the contents of this announcement.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.